Subsequently, several studies including some reviewed here, reported lactadherin as a possible cancer therapeutic target [20,21,22,41,48], either using gene therapy approaches, inhibiting its expression by siRNAs or shRNAs, or by using specific antibodies that block its function and interactions with αvβ3/β5 integrins [45] (Table 1). Here, MFGE8 is linked to cancer.